Metotrexato, yellow powder Ph. Eur., USP

Proveedor: MP Biomedicals

ICNA0219985590EA 1515 EUR
ICNA0219985590 ICNA0219985580 ICNA0219985591 ICNA0219985525 ICNA0219985510 ICNA0219985501
Metotrexato, yellow powder Ph. Eur., USP

Methotrexate is a cell cycle arresting agent with varying effects. Methotrexate has been reported to arrest the cell cycle in late G1/S thus leading to the inhibition of the synthesis of DNA, RNA, thymidylates, and proteins. The main mechanism of action is reported to involve the inhibition of enzymes involved in purine metabolism which leads to the accumulation of adenosine or the suppression of intercellular adhesion molecule expression by T cells. Additionally, this compound has been observed to inhibit DHFR.
Methotrexate is used for chemotherapy either alone or in combination with other agents. It is effective for the treatment of a number of cancers including: breast, head and neck, leukemia, lymphoma, lung, osteosarcoma, bladder, and trophoblastic neoplasms. It is also used in treatment of autoimmune diseases, ectopic pregnancy, and for the induction of medical abortions. It is used to inhibit dihydrofolate reductase in DHFR-based protein expression systems. Also effective in treatment of pyrimethamine-resistant Plasmodium vivax malaria parasites.
Potent inhibitor of dihydrofolate reductase and agent for antitumor studies. Use to inhibit dihydrofolate reductase in DHFR-based protein expression systems. Also shows immunosuppressive effects in, e.g., rheumatoid arthritis.
Methotrexate is an allosteric inhibititor of dihydrofolate reductase (DHFR), the enzyme that catalyzes the conversion of dihydrofolate to tetrahydrofolate. Since tetrahydrolfolate is required for purine and pyrimidine synthesis, methotrexate treatment results in the inhibition of DNA and RNA synthesis.

  • USP and EP Grade
  • Practically insoluble in water, ethanol, chloroform and diethyl ether; freely soluble in dilute solutions of alkaline hydroxides and carbonates; soluble in dilute hydrochloric acid.
  • Store at + 4 °C. Protect from light.

Formula: C₂₀H₂₂N₈O₅
MW: 454,44 g/mol
Temperatura de almacenaje: Nevera
Número MDL: MFCD00150847
Núm. CAS: 59-05-2
UN: 1544
ADR: 6.1,III

Order Now

Resultados test especificaciones

Identity Test A USP Passes
Identity Test C EP Passes
Identity Test A EP Passes
Identity Test B USP Passes
Identity Test B EP Passes
Specific Rotation (anhydrous basis) USP +19° to +24°
Water USP ≤12.0%
Water EP ≤13.0%
Related Substances EP Passes
(R)-Methotrexate EP ≤3.0%
Heavy Metals EP ≤50 ppm
Sulfated Ash, Residue on Igntion EP, USP ≤0.1%
Organic Impurities USP Passes
Methotrexate Content (anhydrous basis as C20H22N8O5) USP 98-102.0%

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Más About VWR